Acceleron to Webcast Presentation at Leerink Partners Rare Disease Roundtable

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced it will present a corporate overview at the Leerink Partners Rare Disease Roundtable on Wednesday, October 1, 2014 at 10:15 a.m. EDT at Le Parker Meridien Hotel in New York City.

A live audio webcast of the presentation will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (http://investor.acceleronpharma.com/events.cfm).

A replay of the webcast will also be available from Acceleron’s website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta (TGF-β) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical protein therapeutic candidates with novel mechanisms of action. These protein therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com.